Randal A. Hassler

Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA.

Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.